OncoCyte Corp Reports Q3 2024 Earnings and Strategic Updates
Company Announcements

OncoCyte Corp Reports Q3 2024 Earnings and Strategic Updates

OncoCyte Corp ( (OCX) ) has released its Q3 earnings. Here is a breakdown of the information OncoCyte Corp presented to its investors.

OncoCyte Corporation is a California-based diagnostics technology company focused on developing and commercializing genetic tests for oncology and transplant applications, with innovative products such as VitaGraft and DetermaIO. Recently, OncoCyte released its earnings report for the quarter ended September 30, 2024, highlighting significant financial metrics and strategic developments. The company reported a net revenue of $115,000 for the quarter, a drop from the previous year’s $429,000, reflecting challenges in revenue generation. Meanwhile, operating expenses surged to $13.6 million, leading to a net loss of $13.5 million. Despite the losses, OncoCyte has been actively seeking capital, raising approximately $9.9 million through private placements and at-the-market offerings, and plans to continue financing its operations through strategic partnerships and equity offerings. Looking ahead, OncoCyte’s management is focused on completing development and expanding the commercialization of its products, despite the ongoing financial challenges, aiming to improve its financial health and market position.

Related Articles
TheFlyOncoCyte reports Q3 EPS (98c), consensus (44c)
Brian AndersonOCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App